News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
330,024 Results
Type
Article (22989)
Company Profile (305)
Press Release (306730)
Section
Business (95176)
Career Advice (1319)
Deals (16125)
Drug Delivery (63)
Drug Development (55251)
Employer Resources (94)
FDA (7250)
Job Trends (6759)
News (170781)
Policy (13253)
Tag
Academia (1411)
Alliances (25441)
Alzheimer's disease (953)
Approvals (7235)
Artificial intelligence (127)
Bankruptcy (128)
Best Places to Work (5826)
Biotechnology (252)
Breast cancer (162)
Cancer (1262)
Cardiovascular disease (109)
Career advice (1090)
CAR-T (103)
Cell therapy (291)
Clinical research (44125)
Collaboration (485)
Compensation (189)
COVID-19 (1594)
C-suite (128)
Data (1239)
Diabetes (142)
Diagnostics (2658)
Earnings (35817)
Employer resources (87)
Events (53804)
Executive appointments (386)
FDA (7838)
Funding (458)
Gene therapy (215)
GLP-1 (445)
Government (1765)
Healthcare (8813)
Infectious disease (1660)
Inflammatory bowel disease (114)
Interviews (274)
IPO (8498)
Job creations (1283)
Job search strategy (884)
Layoffs (259)
Legal (2173)
Lung cancer (193)
Manufacturing (139)
Medical device (4270)
Medtech (4271)
Mergers & acquisitions (7892)
Metabolic disorders (408)
Neuroscience (1309)
NextGen: Class of 2025 (2917)
Non-profit (1506)
Northern California (1439)
Obesity (228)
Opinion (188)
Parkinson's disease (100)
Patents (96)
People (29171)
Phase I (15024)
Phase II (20311)
Phase III (13539)
Pipeline (554)
Postmarket research (1091)
Preclinical (6336)
Radiopharmaceuticals (221)
Rare diseases (275)
Real estate (1908)
Regulatory (10390)
Research institute (1291)
Resumes & cover letters (233)
Series A (89)
Southern California (1264)
Startups (2244)
United States (11697)
Vaccines (328)
Weight loss (156)
Date
Today (6)
Last 7 days (388)
Last 30 days (1634)
Last 365 days (22806)
2025 (2955)
2024 (23073)
2023 (25349)
2022 (33394)
2021 (34554)
2020 (30199)
2019 (21668)
2018 (15929)
2017 (16833)
2016 (15057)
2015 (17986)
2014 (13130)
2013 (9497)
2012 (9776)
2011 (9965)
2010 (9204)
Location
Africa (387)
Asia (20024)
Australia (3633)
California (3292)
Canada (1060)
China (303)
Colorado (127)
Connecticut (150)
Europe (44720)
Florida (376)
Georgia (105)
Illinois (230)
Indiana (136)
Maryland (463)
Massachusetts (2557)
Michigan (103)
Minnesota (154)
New Jersey (836)
New York (924)
North Carolina (528)
Northern California (1439)
Ohio (111)
Pennsylvania (635)
South America (468)
Southern California (1264)
Texas (382)
Washington State (302)
330,024 Results for "turning point therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Bluebird Faces Cash Gap With Breakeven Point in Sight
Bluebird has just two quarters until it’s out of cash. Executives are looking for financing to extend that runway to a projected breakeven point before the end of 2025, with analysts worried they won’t make it.
November 15, 2024
·
4 min read
·
Annalee Armstrong
Biotech Beach
Turn Therapeutics Atopic Dermatitis Candidate Reduces Disease Severity by 57% In-Vivo
In a widely cited in-vivo model of atopic dermatitis, Turn Therapeutics’ atopic dermatitis candidate showed a dramatic reduction in disease severity versus placebo.
June 20, 2024
·
2 min read
Press Releases
Cagent Vascular Initiates the Serranator® POINT FORCE Observational Registry
January 28, 2025
·
2 min read
Press Releases
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma
December 12, 2024
·
5 min read
Drug Development
Molecular Glue Degraders at Inflection Point as Pharma Dives In
Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively investing billions in hopes of treating cancer, Alzheimer’s disease, cardiometabolic disease and more.
December 16, 2024
·
6 min read
·
Kate Goodwin
Job Trends
Difficult Market Turns More Biopharma Leaders to Fractional Roles, Say Experts
For reasons including downsizing, avoiding retirement and a tight labor market, senior-level biopharma professionals are increasingly turning to fractional roles, according to two recruitment experts.
August 28, 2024
·
4 min read
·
Angela Gabriel
Press Releases
Turn Therapeutics Achieves 24-Hour Stability for Live Vaccine in Intranasal Oil Suspension at Room Temperature, Marking Major Milestone Toward Improving Vaccine Access
February 5, 2025
·
3 min read
Biotech Bay
Radiance Therapeutics to Attend LSI USA ’24 Emerging Medtech Summit in Dana Point, CA
Radiance Therapeutics, Inc. , is delighted to announce that its CEO, Laurence Marsteller MD, will be representing the company at the LSI USA ’24 Emerging Medtech Summit, which will take place on March 18-22, 2024 in Dana Point, California.
March 5, 2024
·
1 min read
Biotech Beach
Turn Therapeutics invites public investment for expansion of flagship wound formula into eczema, toenail fungus
Turn Therapeutics launched its first public investment campaign today to fund clinical trials of its Food and Drug Administration-cleared antimicrobial ointment for two potential new drug indications: moderate to severe eczema and onychomycosis, or toenail fungus.
May 22, 2024
·
3 min read
Deals
Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. (“Turning Point”), in an all-cash transaction.
August 17, 2022
·
6 min read
1 of 33,003
Next
